Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 15 |
| List of Tables | 14 | 2 |
| List of Figures | 16 | 1 |
| Introduction | 17 | 1 |
| Global Markets Direct Report Coverage | 17 | 1 |
| Huntington Disease Overview | 18 | 1 |
| Therapeutics Development | 19 | 2 |
| Pipeline Products for Huntington Disease Overview | 19 | 1 |
| Pipeline Products for Huntington Disease Comparative Analysis | 20 | 1 |
| Huntington Disease Therapeutics under Development by Companies | 21 | 4 |
| Huntington Disease Therapeutics under Investigation by Universities/Institutes | 25 | 2 |
| Huntington Disease Pipeline Products Glance | 27 | 3 |
| Late Stage Products | 27 | 1 |
| Clinical Stage Products | 28 | 1 |
| Early Stage Products | 29 | 1 |
| Huntington Disease Products under Development by Companies | 30 | 4 |
| Huntington Disease Products under Investigation by Universities/Institutes | 34 | 1 |
| Huntington Disease Companies Involved in Therapeutics Development | 35 | 52 |
| Addex Therapeutics Ltd | 35 | 1 |
| AFFiRiS AG | 36 | 1 |
| Angita B.V. | 37 | 1 |
| Astellas Pharma Inc. | 38 | 1 |
| Azevan Pharmaceuticals, Inc. | 39 | 1 |
| BioCrea GmbH | 40 | 1 |
| BioMarin Pharmaceutical Inc. | 41 | 1 |
| BrainStorm Cell Therapeutics Inc. | 42 | 1 |
| Diffusion Pharmaceuticals Inc. | 43 | 1 |
| EncephRx, Inc. | 44 | 1 |
| Evotec AG | 45 | 1 |
| Galenea Corp. | 46 | 1 |
| Genervon Biopharmaceuticals, LLC | 47 | 1 |
| Immungenetics AG | 48 | 1 |
| Ionis Pharmaceuticals, Inc. | 49 | 1 |
| Ipsen S.A. | 50 | 1 |
| Kadmon Corporation, LLC | 51 | 1 |
| KineMed, Inc. | 52 | 1 |
| Living Cell Technologies Limited | 53 | 1 |
| Medesis Pharma S.A. | 54 | 1 |
| Mitochon Pharmaceuticals, Inc. | 55 | 1 |
| Neuralstem, Inc. | 56 | 1 |
| Neurimmune Holding AG | 57 | 1 |
| NeuroNascent, Inc. | 58 | 1 |
| New World Laboratories, Inc. | 59 | 1 |
| nLife Therapeutics, S.L. | 60 | 1 |
| NsGene A/S | 61 | 1 |
| Omeros Corporation | 62 | 1 |
| Oryzon Genomics S.A. | 63 | 1 |
| Otsuka Holdings Co., Ltd. | 64 | 1 |
| Pfizer Inc. | 65 | 1 |
| PharmatrophiX, Inc. | 66 | 1 |
| ProQR Therapeutics N.V. | 67 | 1 |
| QR Pharma, Inc. | 68 | 1 |
| Raptor Pharmaceutical Corp. | 69 | 1 |
| reMYND NV | 70 | 1 |
| Rhenovia Pharma Limited | 71 | 1 |
| Sangamo BioSciences, Inc. | 72 | 1 |
| SOM Innovation Biotech SL | 73 | 1 |
| Spark Therapeutics, Inc. | 74 | 1 |
| Teva Pharmaceutical Industries Ltd. | 75 | 1 |
| TyrNovo Ltd. | 76 | 1 |
| Ultragenyx Pharmaceutical Inc. | 77 | 1 |
| UniQure N.V. | 78 | 1 |
| Vaccinex, Inc. | 79 | 1 |
| Vertex Pharmaceuticals Incorporated | 80 | 1 |
| VistaGen Therapeutics , Inc. | 81 | 1 |
| VivaCell Biotechnology Espana S.L. | 82 | 1 |
| Voyager Therapeutics, Inc. | 83 | 1 |
| Vybion, Inc. | 84 | 1 |
| WAVE Life Sciences Ltd. | 85 | 1 |
| Wellstat Therapeutics Corporation | 86 | 1 |
| Huntington Disease Therapeutics Assessment | 87 | 11 |
| Assessment by Monotherapy Products | 87 | 1 |
| Assessment by Target | 88 | 3 |
| Assessment by Mechanism of Action | 91 | 3 |
| Assessment by Route of Administration | 94 | 2 |
| Assessment by Molecule Type | 96 | 2 |
| Drug Profiles | 98 | 132 |
| AK-7 - Drug Profile | 98 | 1 |
| Product Description | 98 | 1 |
| Mechanism of Action | 98 | 1 |
| R&D Progress | 98 | 2 |
| AMT-130 - Drug Profile | 100 | 1 |
| Product Description | 100 | 1 |
| Mechanism of Action | 100 | 1 |
| R&D Progress | 100 | 1 |
| Antisense Oligonucleotide 1 to Inhibit Huntingtin Protein for Huntington Disease - Drug Profile | 101 | 1 |
| Product Description | 101 | 1 |
| Mechanism of Action | 101 | 1 |
| R&D Progress | 101 | 1 |
| Antisense Oligonucleotide 2 to Inhibit Huntingtin Protein for Huntington Disease - Drug Profile | 102 | 1 |
| Product Description | 102 | 1 |
| Mechanism of Action | 102 | 1 |
| R&D Progress | 102 | 1 |
| Antisense Oligonucleotide to Inhibit HTT for Huntington Disease - Drug Profile | 103 | 1 |
| Product Description | 103 | 1 |
| Mechanism of Action | 103 | 1 |
| R&D Progress | 103 | 1 |
| Antisense Oligonucleotides to Inhibit Huntingtin Protein for Huntington Disease - Drug Profile | 104 | 1 |
| Product Description | 104 | 1 |
| Mechanism of Action | 104 | 1 |
| R&D Progress | 104 | 1 |
| ASP-2905 - Drug Profile | 105 | 1 |
| Product Description | 105 | 1 |
| Mechanism of Action | 105 | 1 |
| R&D Progress | 105 | 1 |
| AV-101 - Drug Profile | 106 | 1 |
| Product Description | 106 | 1 |
| Mechanism of Action | 106 | 1 |
| R&D Progress | 106 | 2 |
| AVP-786 - Drug Profile | 108 | 1 |
| Product Description | 108 | 1 |
| Mechanism of Action | 108 | 1 |
| R&D Progress | 108 | 2 |
| BN-82451 - Drug Profile | 110 | 1 |
| Product Description | 110 | 1 |
| Mechanism of Action | 110 | 1 |
| R&D Progress | 110 | 1 |
| Carbenoxolone sodium - Drug Profile | 111 | 1 |
| Product Description | 111 | 1 |
| Mechanism of Action | 111 | 1 |
| R&D Progress | 111 | 1 |
| Cell Therapy for Huntington Disease, Amyotropic Lateral Sclerosis and Parkinson's Disease - Drug Profile | 112 | 1 |
| Product Description | 112 | 1 |
| Mechanism of Action | 112 | 1 |
| R&D Progress | 112 | 1 |
| CNB-001 - Drug Profile | 113 | 1 |
| Product Description | 113 | 1 |
| Mechanism of Action | 113 | 1 |
| R&D Progress | 113 | 2 |
| CP-2 - Drug Profile | 115 | 1 |
| Product Description | 115 | 1 |
| Mechanism of Action | 115 | 1 |
| R&D Progress | 115 | 1 |
| cysteamine DR - Drug Profile | 116 | 1 |
| Product Description | 116 | 1 |
| Mechanism of Action | 116 | 1 |
| R&D Progress | 116 | 4 |
| deutetrabenazine ER - Drug Profile | 120 | 1 |
| Product Description | 120 | 1 |
| Mechanism of Action | 120 | 1 |
| R&D Progress | 120 | 2 |
| ED-11 - Drug Profile | 122 | 1 |
| Product Description | 122 | 1 |
| Mechanism of Action | 122 | 1 |
| R&D Progress | 122 | 1 |
| ENC-1001 - Drug Profile | 123 | 1 |
| Product Description | 123 | 1 |
| Mechanism of Action | 123 | 1 |
| R&D Progress | 123 | 1 |
| fisetin - Drug Profile | 124 | 1 |
| Product Description | 124 | 1 |
| Mechanism of Action | 124 | 1 |
| R&D Progress | 124 | 1 |
| Gene Therapy for Huntington Disease - Drug Profile | 125 | 1 |
| Product Description | 125 | 1 |
| Mechanism of Action | 125 | 1 |
| R&D Progress | 125 | 1 |
| Gene Therapy to Inhibit Huntingtin Protein for Huntington Disease - Drug Profile | 126 | 1 |
| Product Description | 126 | 1 |
| Mechanism of Action | 126 | 1 |
| R&D Progress | 126 | 1 |
| GM-609 - Drug Profile | 127 | 1 |
| Product Description | 127 | 1 |
| Mechanism of Action | 127 | 1 |
| R&D Progress | 127 | 1 |
| INT-41 - Drug Profile | 128 | 1 |
| Product Description | 128 | 1 |
| Mechanism of Action | 128 | 1 |
| R&D Progress | 128 | 2 |
| IONIS-HTTRx - Drug Profile | 130 | 1 |
| Product Description | 130 | 1 |
| Mechanism of Action | 130 | 1 |
| R&D Progress | 130 | 1 |
| JM-6 - Drug Profile | 131 | 1 |
| Product Description | 131 | 1 |
| Mechanism of Action | 131 | 1 |
| R&D Progress | 131 | 1 |
| JR-100 - Drug Profile | 132 | 1 |
| Product Description | 132 | 1 |
| Mechanism of Action | 132 | 1 |
| R&D Progress | 132 | 1 |
| JRP-655 - Drug Profile | 133 | 1 |
| Product Description | 133 | 1 |
| Mechanism of Action | 133 | 1 |
| R&D Progress | 133 | 1 |
| JRP-900 - Drug Profile | 134 | 1 |
| Product Description | 134 | 1 |
| Mechanism of Action | 134 | 1 |
| R&D Progress | 134 | 1 |
| KL-00148 - Drug Profile | 135 | 1 |
| Product Description | 135 | 1 |
| Mechanism of Action | 135 | 1 |
| R&D Progress | 135 | 1 |
| laquinimod sodium - Drug Profile | 136 | 1 |
| Product Description | 136 | 1 |
| Mechanism of Action | 136 | 1 |
| R&D Progress | 136 | 4 |
| lithium citrate - Drug Profile | 140 | 1 |
| Product Description | 140 | 1 |
| Mechanism of Action | 140 | 1 |
| R&D Progress | 140 | 1 |
| LM-22A4 - Drug Profile | 141 | 1 |
| Product Description | 141 | 1 |
| Mechanism of Action | 141 | 1 |
| R&D Progress | 141 | 2 |
| LM11A-31BHS - Drug Profile | 143 | 1 |
| Product Description | 143 | 1 |
| Mechanism of Action | 143 | 1 |
| R&D Progress | 143 | 2 |
| MP-101 - Drug Profile | 145 | 1 |
| Product Description | 145 | 1 |
| Mechanism of Action | 145 | 1 |
| R&D Progress | 145 | 1 |
| NI-302 - Drug Profile | 146 | 1 |
| Product Description | 146 | 1 |
| Mechanism of Action | 146 | 1 |
| R&D Progress | 146 | 1 |
| NNI-362 - Drug Profile | 147 | 1 |
| Product Description | 147 | 1 |
| Mechanism of Action | 147 | 1 |
| R&D Progress | 147 | 2 |
| NNI-370 - Drug Profile | 149 | 1 |
| Product Description | 149 | 1 |
| Mechanism of Action | 149 | 1 |
| R&D Progress | 149 | 1 |
| noscapine - Drug Profile | 150 | 1 |
| Product Description | 150 | 1 |
| Mechanism of Action | 150 | 1 |
| R&D Progress | 150 | 1 |
| NP-42T - Drug Profile | 151 | 1 |
| Product Description | 151 | 1 |
| Mechanism of Action | 151 | 1 |
| R&D Progress | 151 | 1 |
| NsG-33 - Drug Profile | 152 | 1 |
| Product Description | 152 | 1 |
| Mechanism of Action | 152 | 1 |
| R&D Progress | 152 | 1 |
| NSI-566 - Drug Profile | 153 | 1 |
| Product Description | 153 | 1 |
| Mechanism of Action | 153 | 1 |
| R&D Progress | 153 | 2 |
| NT-219 - Drug Profile | 155 | 1 |
| Product Description | 155 | 1 |
| Mechanism of Action | 155 | 1 |
| R&D Progress | 155 | 1 |
| NTCELL - Drug Profile | 156 | 1 |
| Product Description | 156 | 1 |
| Mechanism of Action | 156 | 1 |
| R&D Progress | 156 | 2 |
| NWL-154 - Drug Profile | 158 | 1 |